Sanofi India shares zoom over 6% in weak market; firm declares Q4 results, board recommends dividend of ₹117 per share

The stock witnessed heavy demand as the company posted a good set of numbers for the December quarter (Q4 FY25). Additionally, the company's board has also recommended a final dividend of ₹117 per equity share of the face value of ₹10 each for the financial year ended December 31, 2024, subject to the approval of shareholders at the ensuing 69th Annual General meeting.

Last seen, the stock was trading at ₹5,102.95 on the BSE, up ₹106.20, or 2.13%.

The market capitalisation stood at ₹11,752.09 crore.

Sanofi India Q4 FY25 Results

Sanofi India reported a consolidated net profit of ₹91.3 crore for the quarter ending December 31, 2024 (Q4 FY25). The figure was down 33.6% as compared to the ₹137.7 crore profit logged in the corresponding quarter of the previous fiscal.

Revenue from operations came in at ₹514.9, up 9.7% against ₹469.2 crore registered in the year-ago period.

Total income for the quarter under review stood at ₹520.8 crore, up 8.8% against ₹478.6 crore reported in the December 2023 quarter.

Basic and diluted earnings per share (EPS) from the continuing operations came in at ₹39.64 against ₹30.26 in the year-ago period.

EBITDA, or earnings before interest, taxes, depreciation, and amortisation, was up 18.8% at ₹118.3 crore against ₹99.6 crore in the December 2023 quarter.

Margin also increased to 23% against 21.2% (YoY).

Sanofi India consumer business demerger

In May 2023, drug firm Sanofi India said its board had approved the demerger of its consumer healthcare business into a separate entity.

The company's board has approved the Scheme of Arrangement between Sanofi India Ltd. (SIL) and its wholly owned subsidiary Sanofi Consumer Healthcare India Ltd. (SCHIL), the drug maker said in a statement.

In September 2024, Sanofi Consumer Healthcare India said it has been listed on the BSE and the National Stock Exchange.

"India's consumer healthcare market has vast potential. SCHIL getting listed on the BSE and NSE marks a critical milestone for us, one that is further expected to strengthen our position and drive sustainable growth within the Indian market," Sanofi Consumer Healthcare India MD Himanshu Bakshi said in a statement.

What management said on Q4 FY25 results

Sanofi India said its diabetes portfolio reported double-digit growth for Toujeo® and a successful launch of Soliqua®, reinstating confidence and strength in its comprehensive diabetes portfolio.

Rodolfo Hrosz, Managing Director, Sanofi India Limited, said, “In a year of significant transformation for the company, we have successfully brought to market Soliqua®—our best-in-class diabetes drug for the premix segment, which has received encouraging acceptance. Our efforts to reach more HCPs through partnerships for the Cardiovascular and CNS (Central Nervous System) categories have advanced as planned, with initial promising results. We will continue to focus on driving further improvement in operating efficiencies while expanding the availability of established and innovative products in India.”

Sanofi India share price trend

Shares of Sanofi India have slipped over 40% in the past 12 months.